Please assess the completion status of the following clinical trial:

Trial Title: Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Clinical symptoms:~   * Angina \< 12 h persistent Angina \> 30 min.~2. ECG-Criteria:~   * ST-elevation \> 1mm in ≥ 2 extremity leads~  * ST-elevation \> 2mm in ≥ 2 contiguous anterior leads~3. Informed consent~Exclusion Criteria:~1. No consent~2. Pregnancy~3. Allergy against abciximab, ASA or heparin~4. Active peptic ulcus ventriculi or duodeni~5. Active non-superficial bleeding~6. Major surgical intervention, intracerebral interventions, puncture central artery \< 4 weeks~7. Active internal bleeding~8. Cerebrovascular complications \< 2 years~9. Known coagulation disorders, thrombocytopenia~10. Arteriovenous malformations or aneurysms~11. Severe Liver or renal dysfunction~12. Severe untreated hypertension~13. Active vasculitis~14. Previous thrombolysis \< 12 h

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).